April 4 (Reuters) - Replicel Life Sciences Inc RP.V
* Positive results from Replicel's RCS-01 phase I skin trial are the company's most compelling to date
* Interim trial results lead researchers to conclude that injection of RCS-01 is not only very safe, but also has potential to reverse effects of aging skin Source text for Eikon: ID:nCNWcykTla Further company coverage: RP.V